XOMA Co. (NASDAQ:XOMA) CEO Owen Hughes Sells 21,881 Shares

XOMA Co. (NASDAQ:XOMA) CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the transaction, the chief executive officer now directly owns 34,979 shares in the company, valued at approximately $1,047,621.05. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

XOMA Price Performance

XOMA stock opened at $29.71 on Thursday. XOMA Co. has a 12 month low of $14.33 and a 12 month high of $33.78. The business’s fifty day simple moving average is $28.60 and its two-hundred day simple moving average is $26.84. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

XOMA (NASDAQ:XOMA) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $11.09 million during the quarter, compared to analysts’ expectations of $8.37 million. Equities analysts expect that XOMA Co. will post -0.79 earnings per share for the current year.

Institutional Trading of XOMA

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets grew its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the period. Rhumbline Advisers grew its holdings in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the period. Bank of New York Mellon Corp increased its position in XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after buying an additional 1,968 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of XOMA during the first quarter valued at approximately $212,000. Finally, Ellsworth Advisors LLC purchased a new position in shares of XOMA in the third quarter worth $516,000. Institutional investors own 95.92% of the company’s stock.

Analysts Set New Price Targets

XOMA has been the subject of several research analyst reports. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $117.00 price target on shares of XOMA in a report on Wednesday, October 23rd.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.